Adam Feuerstein

TheStreet.com Senior Columnist

Before joining TheStreet.com in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

Feuerstein graduated from Emory University with a bachelor's degree in political science.

Adam Feuerstein
By This Author:
« Back
Page 1 of 404
Article

Cel-Sci's History of Disappearing Drugs: BioBuzz

By Adam Feuerstein

Will Cel-Sci's flu drug last longer than its other fly-by-night projects?

09:20AM 11/24/09

Article

BioCryst Bull Blames Conspiracy for Stock's Fall: BioBuzz

By Adam Feuerstein

Hedge funds, Wall Street, SEC and FDA out to hurt maker of flu drug, newsletter writer claims.

06:45AM 11/24/09

Article

Poniard Finds Cash to Keep Lights On: BioBuzz

By Adam Feuerstein

Poniard faces a cash-crunch situation after a failed drug test last week.

12:59PM 11/23/09

Article

Cel-Sci Chairman Sells Stock, Despite Sweetheart Loan Deal: BioBuzz

By Adam Feuerstein

Shareholders are on the hook for a generous loan repayment to Cel-Sci's founder.

10:14AM 11/23/09

Article

FDA Issues New Obesity Drug Heart Warning: BioBuzz

By Adam Feuerstein

Safety of Abbott's Meridia may heighten concerns for all weight-loss drugs

08:15AM 11/23/09

Article

Biotech Stock Mailbag: FDA Playbook

By Adam Feuerstein

Smart drug and biotech companies keep the FDA abreast of their clinical trial program throughout the long drug-development process.

06:01AM 11/20/09

Article

U.S. Sees Low Demand for BioCryst Flu Drug

By Adam Feuerstein

Peaking flu season could mean no need for further peramivir orders.

11:12AM 11/18/09

Article

Another Genzyme Drug Goes Kaboom: BioBuzz

By Adam Feuerstein

Company halts development of kidney disease drug following poor test results.

08:05AM 11/18/09

Article

Vivus Seeks Faster ED Drug: Biobuzz

By Adam Feuerstein

Company says ED drug met all goals in phase III study.

06:42AM 11/18/09

Article

Genzyme's Termeer: Worst Biotech CEO of '09

By Adam Feuerstein

Genzyme CEO Henri Termeer is Adam Feuerstein's Worst Biotech CEO of the Year for 2009.

12:31PM 11/17/09

« Back
Page 1 of 404
Dow Jones S&P 500 NASDAQ 10-Year Note
10,464.40 1,110.63 2,176.05 32.79
Oil *
77.05
UP
30.69
UP
4.98
UP
6.87
DOWN
0.38
10 Yr
3.28%
SPDR Gold
116.62
+0.29%
+0.45%
+0.32%
-1.15%
Data delayed 20 minutes

Brokerage Partners